Terug
naar lijst
- Auteur
- NVMO-commissie BOM
- Printdatum
- 19-06-2025
- E-pubdatum
- 19-06-2025
Plaatsbepaling immuuncheckpointremmers in patiënten met inoperabel of gemetastaseerd endometriumcarcinoom
Huidige beschikbaarheid immuuncheckpointremmers De komst van immuuncheckpointremmers (ICI’s) heeft een nieuw tijdperk in het behandellandschap van gevorderd endometriumcarcinoom (EC) gemarkeerd.1 … Verder lezen “Plaatsbepaling immuuncheckpointremmers in patiënten met inoperabel of gemetastaseerd endometriumcarcinoom”
- Colombo N, Caruso G, Jalving M. Immune checkpoint inhibitors in endometrial cancer: A Cinderella story. Ann Oncol 2024:35:686-8.
- The Cancer Genome Atlas Research Network, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
- Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386:437-48.
- Zeverijn LJ, Geurts BS, Battaglia TW et al. The innate immune landscape of dMMR/MSI cancers predicts the outcome of nivolumab treatment: Results from the Drug Rediscovery Protocol. Clin Cancer Res 2024;30(19):4339-51.
- Standpunt nivolumab (Opdivo®) voor de behandeling van bepaalde patiënten met dMMR- of MSI-tumoren | Advies | Zorginstituut Nederland (geraadpleegd 27-03 2025)
- Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388:2145-58.
- Powell MA, Bjørge L, Willmott L, et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatinpaclitaxel in the randomized ENGOTEN6/ GOG-3031/RUBY trial. Ann Oncol. 2024;35:728-38.
- Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388: 2159-70.
- Eskander RN, Sill MW, Beffa L et al. Pembrolizumab plus chemotherapy in advance or recurrent endometroial cancer: overall survival and exploratory analyses of the NRGGYO018 phase 3 randomised trial. Nat Med. 2025 Mar 5. doi: 10.1038/s41591-025-03566-1. Epub ahead of print. PMID: 40044930.
- Colombo N, Paolo N, Harano K, et al. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(9): 1135-46.
- Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J Clin Oncol. 2024;42:283-99.
- Bogani G, Monk BJ, Powell MA, et al. Adding immunotherapy to first line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024;35:414-28.
- Kaya M, Schaddelee MCA, Creutzberg CL et al. Efficacy of PD(L)1 inhibition in the treatment of endometrial cancer across molecular classes: a systematic review and metaanalysis. Int J Gynecol Cancer. 2025 Mar 1:101759. doi: 10.1016/ j. ijgc.2025.101759. Epub ahead of print. PMID: 40199646.
- Mirza MR, Coleman RL, Hanker L et al. ENGOTEN6/GOG3031/NSGOCTURUBY part 2: A phase III, randomized, doubleblind, study of dostarlimab + carboplatinpaclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatinpaclitaxel followed by PBO in recurrent of advanced endometrial cancer (EC). Ann Oncol 2021:32; S770-1.